Until now, the discovery of antibodies has been based on painstaking work in the laboratory. By replacing it with artificial intelligence algorithms, the creation of drugs can be significantly accelerated.
In the latest issue of Forbes you can read the story of one of our founders - Konrad Krawczyk, who in partnership with his family team built the Natural Antibody company.
"The value of the antibody drugs market is estimated at $150 billion and is expected to double in the coming years" Wojciech Pysiewicz, co-founder of the venture capital fund WP2 Investments, which is an investor in NaturalAntibody, told Forbes magazine. This company offers a unique tool for finding and optimizing antibodies, thanks to the world's largest antibody database and artificial intelligence modules.
Reducing costs and accelerating drug production through the use of technology is a great opportunity not only for the biotechnology sector, but also for patients, who could gain access to innovative therapies more quickly.
The therapeutic power of antibodies lies in the fact that the principle of their action is identical to those produced by the body, which struggle with the diseases that attack us every day. Hence their potential in the fight against oncological and autoimmune diseases, for which there is still a lack of good drugs.
In March last year, the company entered the market with a fully functional product. – By wasting less time on services, we can scale our analytical platform more. At the same time, we are constantly improving it. In six months, we increased its functionality by 25 percent.There is a joke in the company that we have a product roadmap of ideas until 2035 – says Konrad Krawczyk. – Since June, we have literally "untied the bag" with contracts.
We are glad that, as the example of Konrad Krawczyk shows, young Polish founders with great potential go to study in the best European centres, and then become the initiators and "brains" of such innovative projects on a global scale as NaturalAntibody - says Wojciech Pysiewicz, co-founder of the WP2 Investments fund. - We are with NaturalAntibody through thick and thin, committed to its development and proud of its every success.
We encourage you to read the article in the March issue of Forbes - you will find out exactly how this interdisciplinary-minded scientist came to be the founder of a biotechnology company, why he treats the area of his scientific work as extremely attractive, and what cooperation with Big Pharma looks like.
